Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pharmaceutics ; 14(12)2022 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-36559304

RESUMEN

Sustained-release formulations of decoquinate were evaluated for the long-term prophylaxis of malaria. In the initial experiment, mice were protected from liver-stage Plasmodium infection by intramuscular administration of a lipids-based formulation at a dose of decoquinate 200 mg/kg. The mice that were inoculated with Plasmodium berghei sporozoites 34 days after the administration of a one-time drug dose were continuously monitored for 60 days and shown to be free of Plasmodium parasites. The optimized formulation for the sustained release of decoquinate was prepared by hot melt extrusion, constructed by lipids including cholesterol and mono or diglycerides, and had a drug load of 20 to 40% and particle size of 30 to 50 µm. Decoquinate of the lipids-based formulation was slowly released in vitro at a constant rate for the duration of two months, and was examined and continuously exposed at a therapeutic level in the blood for as long as 4 to 6 months. Further evaluation showed that the lipids-based formulation at doses of decoquinate 100 to 150 mg/kg could protect mice from Plasmodium infection for a period of 120 days. It is the first time that cholesterol has been used for a controlled drug delivery system of decoquinate. The results may provide useful information, not only for preparing a formulation of long-acting decoquinate but also in general for developing a controlled drug release system. The one-time administration of pharmaceutical agents in such a slow-release system may serve patients with no concerns about compliance.

2.
Antimicrob Agents Chemother ; 66(6): e0221821, 2022 06 21.
Artículo en Inglés | MEDLINE | ID: mdl-35658489

RESUMEN

Liver-stage Plasmodium in humans is an early stage of malarial infection. Decoquinate (DQ) has a potent multistage antimalarial activity. However, it is practically water insoluble. In this study, the hot-melt extrusion (HME) approach was employed to prepare solid dispersions of DQ to improve oral bioavailability. The DQ dispersions were homogeneous in an aqueous suspension that contained most DQ (>90%) in the aqueous phase. Soluplus, a solubilizer, was found compatible with DQ in forming nanoparticle formulations during the HME process. Another excipient HPMC AS-126 was also proven to be suitable for making DQ nanoparticles through HME. Particle size and antimalarial activity of HME DQ suspensions remained almost unchanged after storage at 4°C for over a year. HME DQ was highly effective at inhibiting Plasmodium infection in vitro at both the liver stage and blood stage. HME DQ at 3 mg/kg by oral administration effectively prevented Plasmodium infection in mice inoculated with Plasmodium berghei sporozoites. Orally administered HME DQ at 2,000 mg/kg to mice showed no obvious adverse effects. HME DQ at 20 mg/kg orally administered to rats displayed characteristic distributions of DQ in the blood with most DQ in the blood cells, revealing the permeability of HME DQ into the cells in relation to its antimalarial activity. The DQ dispersions may be further developed as an oral formulation targeting Plasmodium infection at the liver stage.


Asunto(s)
Antimaláricos , Decoquinato , Malaria , Animales , Antimaláricos/farmacología , Antimaláricos/uso terapéutico , Decoquinato/farmacología , Composición de Medicamentos , Calor , Hígado , Malaria/tratamiento farmacológico , Ratones , Plasmodium berghei , Ratas , Solubilidad
3.
Malar J ; 21(1): 24, 2022 Jan 24.
Artículo en Inglés | MEDLINE | ID: mdl-35073922

RESUMEN

BACKGROUND: Severe malaria caused by Plasmodium falciparum leads to most malaria-related deaths globally. Decoquinate (DQ) displays strong activity against multistage infection by Plasmodium parasites. However, the development of DQ as an oral dosage form for the treatment of malaria at the blood stage has not been successful. In this study, liposome formulations of DQ were created for intravenous (IV) injection to suppress Plasmodium berghei, a parasite that causes severe malaria in mice. METHODS: DQ liposomes were prepared by conventional ethanol injection method with slight modifications and encapsulation efficiency evaluated by the well-established centrifugation method. Potency of the DQ liposomes against P. falciparum was assessed in vitro using freshly isolated human red blood cells. The efficacy of the DQ liposomes was examined in the mouse model of severe malaria. RESULTS: The DQ liposomes were around 150 nm in size and had the encapsulation efficiency rates > 95%. The freshly prepared and lyophilized liposomes were stable after storage at - 20 °C for 6 months. The liposomes were shown to have excellent activity against P. falciparum in vitro with DQ IC50 0.91 ± 0.05 nM for 3D7 (chloroquine sensitive strain) and DQ IC50 1.33 ± 0.14 nM for Dd2 (multidrug resistant strain), which were 18- and 14-fold more potent than artemisinin, respectively. Mice did not have any signs of toxicity after receiving high dose of the liposomes (DQ 500 mg/kg per mouse) by IV injection. In the mouse model of severe malaria, the liposomes had impressive efficacy against P. berghei with DQ ED50 of 0.720 mg/kg. CONCLUSION: The DQ liposomes prepared in this study were stable for long term storage and safe for IV injection in mammalian animals. The newly created liposome formulations had excellent activity against Plasmodium infection at the blood-stage, which encourages their application in the treatment of severe malaria.


Asunto(s)
Antimaláricos/farmacología , Decoquinato/farmacología , Eritrocitos/efectos de los fármacos , Liposomas/uso terapéutico , Malaria Falciparum/tratamiento farmacológico , Plasmodium falciparum/efectos de los fármacos , Animales , Animales no Consanguíneos , Eritrocitos/parasitología , Femenino , Humanos , Masculino , Ratones
4.
Artículo en Inglés | MEDLINE | ID: mdl-22929864

RESUMEN

A new resonance light scattering (RLS) method for emodin determination with cationic surfactant cetyltrimethylammonium bromide (CTAB) as probe has been developed. In Britton-Robinson buffer (pH 6.5) medium, emodin reacted with cationic surfactant CTAB and formed the emodin-CTAB complex. The complex aggregated together through hydrophobic forces and causing great enhancement of RLS signals with the maximum peak located at about 350 nm. The enhanced RLS intensities were found to be proportional to the concentration of emodin in the range of 0.54-9.72 µg ml(-1) with the detection limit (3σ) of 10.3 ng ml(-1). In this work, the characteristics of RLS, absorption, fluorescence spectra of the system were studied. The optimum reaction condition and the influencing factors on the RLS signal were investigated in detail. The proposed method was applied to the analysis of emodin in synthetic samples and human urine with satisfactory results. Furthermore, the forms of the substances under the experimental condition and the mechanism of the reaction were discussed in detail.


Asunto(s)
Compuestos de Cetrimonio/química , Emodina/análisis , Luz , Sondas Moleculares/química , Óptica y Fotónica/métodos , Dispersión de Radiación , Absorción , Equilibrio Ácido-Base , Calibración , Cetrimonio , Emodina/orina , Humanos , Indicadores y Reactivos , Iones , Límite de Detección , Masculino , Microscopía Electrónica de Rastreo , Peso Molecular , Concentración Osmolar , Espectrometría de Fluorescencia , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA